Vygon, a leading group specialized in the design, manufacturing and marketing of medical devices in neonatology and vascular management clinical specialties, today announces its acquisition of Stiletto®, a new generation of extended‑dwell catheters integrating SlipStream™ technology, from Avia Vascular (Salt Lake City – UT).
This strategic acquisition enhances Vygon’s leadership in vascular access and supports its ambition to accelerate growth in the United States, where extended-dwell catheters represent a significant and rapidly expanding segment of the market. Financial details were not disclosed.
The Stiletto Extended Dwell Catheter (EDC) is a sterile, peripherally inserted single‑use device designed for mid‑duration therapies (<28 days). SlipStream is a patented insertion system designed to replace the traditional Seldinger technique for extended‑dwell catheters.
“Stiletto closes a critical gap in our vascular access offering,” said Thomas Walter, chief corporate officer, international business & offer development at Vygon. “Its SlipStream technology will reshape the way extended‑dwell catheters are inserted, presenting clinicians with a safer, more intuitive technique and delivering significant improvements in patient comfort, safety and care efficiency, fully aligned with Vygon’s mission to Value Life.”
By eliminating guidewires and reducing procedural steps, SlipStream offers clinicians a simpler, safer and more intuitive technique, while delivering significant clinical benefits for patients.
“This acquisition is a decisive step for Vygon as it enhances our leadership in vascular access,” said Ludovic Richard‑Vitton, CEO of Vygon. “By integrating Stiletto into our portfolio, we reinforce our position in this sector, significantly strengthening it in the US, the world’s largest and most dynamic market for midline and extended‑dwell catheters.”
This marks Vygon’s first entry into the extended-dwell catheter segment. Vygon now offers one of the most comprehensive vascular access portfolios worldwide, covering a full continuum of solutions, including standard midlines, extended‑dwell catheters, PICC lines, central venous catheters (CVC), implantable ports, and neonatal and pediatric vascular access devices.
The global market for midline and extended‑dwell catheter solutions is estimated at more than 3 billion dollars in 2024, with an expected CAGR of between 6% and 9% from 2025 to 2030. North America dominated the midline catheters market with the largest revenue share of 40.31% in 2024. The extended-dwell catheter segment is particularly dynamic, driven by the growing need for mid‑term venous access solutions that combine clinical efficiency, safety and cost‑effectiveness.